Royal DSM, a global purpose-led science-based company, pledges to purchase all of its electricity worldwide from renewable sources as well as further reduce greenhouse gas (GHG) emissions from its own operations faster with stringent new 2030 sustainability targets.
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, aims to halve its 2016 greenhouse gas (GHG) emissions from its own operations by 2030. The acceleration of its initial 30% reduction target is based on the strong progress over the past few years. With this step-up DSM continues to be an ambitious climate leader in its sector and the updated target provides a firm foundation for DSM to achieve net-zero by 2050.
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, acquired Erber Group for an enterprise value of €980 million. The transaction – which excludes two smaller units in the Erber Group – is expected to be earnings enhancing in the first year upon completion.
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, launched Dyneema, which is driving the performance of Team Sunweb’s protective cycling jerseys in the 2020 Tour de France. Together with its partners, Team Sunweb and Craft Sportswear, DSM has helped to deliver a jersey that, when combined with a protective baselayer, offers cyclists effective abrasion protection at speeds up to 60kph, while also reducing the severity of open wounds at even higher speeds. In this way, DSM underlines its commitment to protect people and the environment they live in.
Royal DSM, a purpose-led, global science-based company active in Nutrition, Health and Sustainable Living, launched its new, high-quality life’sDHA® SF55-O200DS oil for maternal and early life nutrition solutions. Offering a higher potency, this ingredient contains a minimum of 550 mg/g natural triglyceride DHA (docosahexaenoic acid), allowing manufacturers to achieve equivalent dosages of DHA in smaller product formats and meet the latest maternal nutrition trend for convenient capsule and tablet sizes.
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, completed its acquisition of Glycom A/S, the world’s leading supplier of Human Milk Oligosaccharides (HMO) for an enterprise value of €765 million.
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, Sabic, a global leader in the chemical industry, and UPM Biofuels, a leading producer of sustainable raw materials, signed a partnership that will help to reduce the environmental footprint of Dyneema®, the world’s strongest fiber. The collaboration will see Dyneema® transition to bio-based feedstock leveraging SABIC’s ground-breaking TRUCIRCLETM solutions for certified renewable products. As such, DSM is delivering on its commitment to improve the sustainability footprint of Dyneema®, moving towards a circular, bio-based economy.
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, announces that its new, bio-based self-matting resin, Decovery® SP-2022 XP, has been successfully integrated by coating formulators Ciranova and Arboritec AB into products launched at Domotex 2020. As such, the resin is now successfully enabling easier application and higher aesthetic and functional performance in the flooring market, as well as outperforming conventional market alternatives on sustainability.
Amyris, a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, sold its Vitamin E royalty agreement to Koninklijke DSM N.V. (Royal DSM). This agreement assigns Amyris’s rights to Vitamin E royalties to DSM in exchange for total consideration of approximately $57 million. In addition, DSM and Amyris have agreed to a further manufacturing cooperation for Amyris products at DSM’s Brotas facility that provides additional capacity and lower cost of goods sold with an expected approximate aggregate benefit of $30–$40 million over the next three years. The expected economic benefit of both agreements to Amyris is approximately $90 million.